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Abstract: The discovery of BRCA1 and BRCA2 genes has led to the introduction of increasingly sophisticated 
genetic tests to measure the risk of hereditary breast cancer, among other things. The aim of this study was to 
determine the prevalence of the mutation in 24 women from Córdoba with breast / ovarian cancer (BC / OC) 
and with at least two relatives with breast cancer. Although there are recurrent mutations, which appear 
repeatedly in unrelated families, with highest prevalence as in the Jewish ethnicity, this is the first study on the 
population of the province of Córdoba, Argentina. 
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1. INTRODUCTION 
Breast cancer ranks third in frequency of all patients with cancer in the world and more than six 
hundred thousand new cases are reported each year. In developing countries it is the second most 
common cancer (1). In Argentina it is the leading cause of tumor deaths in women. Each year 
approximately 5,400 women die (1) and it is estimated that about 17,000 new cases (2) are diagnosed. 
It is estimated that 18,000 new cases will occur per year, which represents 17.8% of total cancer 
incidence in Argentina. Argentina, after Uruguay, is the American country with the highest death rate 
from breast cancer (with 20.1 and 24.3 deaths per 100,000 women respectively). While Bolivia, 
Ecuador and Mexico have the lowest rates (with 7.6, 10 and 10.5 deaths per 100,000 women 
respectively) .The highest breast cancer mortality rates are between 50 (41.6 per 100,000 women) and 
80 years old (215.8 per 100,000 women). Breast cancer is the most prevalent cancer in women, with a 
rate of 74 cases per 100,000 women. Over 75% of women with breast cancer have no family history 
of the disease. Breast carcinoma is a heterogeneous neoplasm from clinical, morphological and 
molecular point of view due to the variability in the expression of multiple genes, where each type of 
carcinoma presents its own histopathologic features and biological behavior. Regarding the different 
phenotypical changes a molecular classification in five subtypes has been made, four subtypes of 
clinical relevance (3):1) subtype overexpressing Her2 neu, Her 2 positive 2) Luminal A-like subtype 
3) Luminal B-like subtype 4) Triple negative subtype. The practical importance of the molecular 
classification of breast carcinoma lies in the prognosis of patients. Worse prognosis subtypes are those 
that have an over expression of Her2 neu triple negative, presenting a shorter survival and disease-free 
time. In addition, the triple negative basal subtype has the highest mutation frequency in BRCA1 gene 
and P53 (4). 
For breast cancer early detection is critical because tumors of less than 1 centimeter have up to 90% 
chance of cure. 1% of breast cancers occur in men (5). 
Since the discovery of susceptibility genes for breast cancer (BC) and ovarian cancer (OC), BRCA1 
(17q 21, MIM 113705) and BRCA2 (13q 14, MIM 600185) (6), it is known that 5% BC cases can be 
explained by the existence of pathogenic mutations in these genes. The pattern of genetic 
predisposition that BRCA1 and BRCA2 genes follow is of high penetrance autosomal dominant type, 
in which the inheritance of a single mutation in one of these 2 genes confers a high risk of developing 
the disease throughout life (a 45-85% risk of BC and a 11-63% OC) (7.8). The spectrum of mutations 
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in the BRCA1 and BRCA2 genes can have large differences in different communities due to their 
ethnic diversity (9). Some populations or ethnic groups have founder mutations, from a common 
ancestor, which appear recurrently in most families with BC / OC hereditary of those populations (10, 
11). 
The state of BRCA1 / 2 mutation in subgroups of patients with breast cancer (BC) and ovarian cancer 
(OC) selected by age, family history and ethnicity has been little researched outside Europe and North 
America (12-14), with few reports from South America, where the effects of the founders Native 
American and the multiracial complex demographics of recent immigration, predict a high genetic 
variation (15). In fact, recent studies suggest a role of indigenous descent in patterns BRCA1 / 2 
disease in Central and North America (16-21). Epidemiological data indicate that in Argentina BC 
incidence and mortality (22) is among the highest in the world. Historical records and epidemiological 
and molecular studies point to the variable mix of European, mainly Spanish and Italian, and the 
natives in more than 50% of Argentina's population (15, 23).Regarding the autosomal evidences of 
the mix, the European relation, the Native American and Western Africa in the genetic contribution to 
the Argentinians were estimated at 67.55%, 25.9% and 6.5%, respectively (24). Solano et al (25) 
conducted the first study that describes the genetic variants BRCA1 / BRCA2 in Argentinian patients 
with BC and OC, and highlights a significant impact of new mutations and genetic variants that may 
be regarded as supposedly South American. On the other hand, they confirmed the key role of 
Ashkenazi Jews BRCA1 and BRCA2 in Argentina. 
The aim of this study was to determine the prevalence of the mutation in 24 women from Córdoba 
with BC / OC and with at least two relatives with breast cancer. 
2. PATIENTS AND METHODS 
2.1.Patients: The sample included 24 women , index case (first case study) of the city of Cordoba, 
Argentina with BC / OC. Age range of the sample ranged between 21 and 54 years (x = 29). Inclusion 
criteria were: a) women diagnosed with breast and / or ovarian cancer; b) age not less than 20 years; 
c) to accredit two or more relatives affected with breast cancer from the same lineage (same maternal 
or paternal family line), which was checked by medical and / or death certificate. All participants 
signed an informed consent, in which the study objectives and confidentiality of the results were 
explained. These were delivered to patients personally in a genetic counseling session. 
2.2. DNA extraction from peripheral blood: Each woman incorporated to the research was 
extracted 2.5 ml peripheral blood using vacuum tubes with EDTA as anticoagulant. Genomic DNA 
from peripheral blood leukocytes was isolated using the purification kit (Qiagen, www.qiagen.com) 
after which it was measured with spectrophotometer Nanodrop-1000 (Thermofisher) establishing 
DNA concentration in 1 - 2 µl from samples, with a good purity degree. DNA was amplified through 
PCR (polymerase chain reaction) with specific primers previously described (26) for exons 2, 11 and 
20 of the BRCA1 gene (RefSeq: NM 007294.3, NG 005905.2) and exons 11 and 12 of the BRCA2 
gene (RefSeq: NM 00059.3; NG 012772.2). Then the photographic record of the 12 amplified 
fragments was performed by electrophoresis on agarose gel at 1.8% and visualization in UV 
transilluminator. The amplified products were purified with Wizard SV Gel kit and PCR Clean-Up 
System (Promega) and the fragments corresponding to the 3 exons of the gene BRCA 1 and 2 exons 
of the gene BRCA 2 were sequenced in both directions .Sequencing was performed with Big Dye 
Terminator v1.1 method Cycle Sequencing, technology (Applied Biosystems) with the sequencer ABI 
PRISM 310 Genetic Analyser (Applied Bio systems). The nomenclature used for the description of 
the identified variants follows the Human Genome Variation Society (HGVS) guidelines. Table 1 also 
includes the Cancer Information Core Website Internet (BIC) nomenclature. Unreported sense 
mutations (missense) or those without clinical significance in the BIC database were analyzed with 
the Aling-GVGD program (GVGC alignment analysis) (27). This program is a bioinformatics 
statistical model (predictive free access program) which takes into account the biophysical 
characteristics of proteins and amino acids (composition, polarity, and volume) that compares in 
multiple sequence alignments (multiple sequence alignment MSA) amino acids observed at each 
position, predicting some degree of clinical relevance of reversal substitutions (missense) in the genes 
of interest. The amino acid changes are grouped in a spectrum ranging from a probably pathogenic to 
a probably neutral (without clinical significance) position. For the BRCA1 gene, scores of Align-
GVGD are classified as follows: C65- most likely to be pathogenic, C35 - C55 - less likely to be 
pathogenic, C15 - C25 - low probability of being pathogenic, C0 - least likely to be pathogenic. 
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3. RESULT AND DISCUSSION 
After the analysis of the corresponding electropherograms of the 24 samples included in the study, 9 
variants, detailed in Table, 1 were identified. 
Table1.Variants identified in 24 samples 
Exon Variant (amino 
acid position) 
Variant 
description 
Nucleotide 
according to 
HGVS 
Nucleotide 
according to BIC 
GVGD 
analysis 
11 D693N p.Asp693Asn c.2077G>A 2196G>A CN 
11 S694S p.Ser694Ser c.2082C>T 2201C>T CN 
11 N743Y p.Asn743Try c.2227A>T 2346A>T CN 
11 L771M p.Leu771Met c.2311T>A 2430T>A CN 
11 L771V p.Leu771Val c.2311T>G 2430T>G CN 
11 P871L p.Pro871Leu c.2612C>T 2731C>T CN 
11 E1038G p.Glu1038Gly c.3113G>A 3232G>A CN 
11 L1086X pLeu1086Stop c.3257T>G nt3376T>G MNS 
11 K1183R p.Lys1183Arg c.3548A>G 3667A>G CN 
HGVS: Human Genome Variation Society. 'A' of the initiation codon (ATG) is numbered as 
nucleotide +1 
BIC: Breast Information Core database. 'A' of the initiation codon(ATG) is numbered as nucleotide 
+120 
GVGD analysis: See text description 
CN: Without clinical importance according to BIC(Clinically No important) 
MNS: Nonsense mutation (Nonsense) 
In the sample of all cases studied, in 10/24 patients (40%) nucleotide alterations were not found in the 
analyzed exons and in 15/24 patients (60%) mutational variants were identified that consisted in a 
nucleotide substitution, no insertions or deletions were found. See Table 2. 
From these nucleotide variants, in 2/15 samples (12%) nonsense mutation (nonsense) exon 11 was 
identified, L1086X c.3275T> G, which generates the appearance of a stop codon (stop) and the 
presumed abnormal protein synthesis (truncated protein). The remaining 7 variants correspond to 
nucleotide substitutions without clinical significance according to BIC. See Table1  
Table2.Summary of detected mutations - Gen BRCA 1 - exon 11 
Patie
nt Nº 
No 
Mutation 
Mutation 
D693N S694S N743Y L771V L771M P871L E1038G L1086X K1183
R 
1 +                  
2                 +   
3 +                   
4 +                   
5 +                   
6               +     
7 +                   
8               +   + 
9           +         
10                 +   
11     +   +     +   + 
12               +     
13   +           +   + 
14               +   + 
15   +           +   + 
16               +   + 
17          +         
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18               +   + 
19 +                   
20                   + 
21 +                   
22 +                   
23             + +   + 
24       +       +   + 
Total 10 2 1 1 1 2 1 12 2 10 
% 40 8 4 4 4 8 4 48 12 40 
The extreme complexity and diligence of the study of these two genes in addition to the low 
prevalence of mutations in the population require the careful selection of women from families with 
chances of detecting a genetic alteration. 
Although there is no unanimously established criterion, the main criteria for inherited predisposition 
risks are: a high number of BC and especially OC cases in the family, an early age at diagnosis and 
the presence of male BC, among others. 
In our sample both cases with relevant mutations come from families with a family history of BC and 
OC (Table 3), with mutations only in the BRCA1 gene. The results could be biased due to the low 
number of families analyzed in this group and it would be necessary the study of a greater number of 
families, and to incorporate the full analysis of both genes with the complete sequencing system (Next 
Generation sequencing - NGS) because in both genes the mutations are distributed throughout the 
sequence and differ in each family.  
Table3.Family history of BC / OC and BRCA 1 and BRCA 2 
Patient 
 Nº 
BRCA1 BRCA 2 Tumor Family 
History 
1 Negative Negative Ovarian papillary serous adenocarcinoma No 
2 Positive                      Negative     No Yes 
3 Negative Negative     No Yes 
4 Negative Negative     No Yes 
5 Negative Negative Triple negative breast cancer No 
6 Negative Negative Triple negative breast cancer No 
7 Negative Negative     No Yes 
8 Negative Negative     No Yes 
9 Negative Negative     No Yes 
10 Positive Negative Triple negative breast cancer Yes 
11 Negative Negative Luminal B breast cancer Yes 
12 Negative Negative Triple negative breast cancer Yes 
13 Negative Negative Triple negative breast cancer Yes 
14 Negative Negative Triple negative breast cancer No 
15 Negative Negative No Yes 
16 Negative Negative Triple negative breast cancer Yes 
17 Negative Negative Luminal A breast cancer Yes 
18 Negative Negative Triple negative breast cancer Yes 
19 Negative Negative Triple negative breast cancer Yes 
20 Negative Negative  ovarian cancer No 
21 Negative Negative  Triple negative breast cancer No 
22 Negative Negative     No Yes 
23 Negative Negative     No Yes 
24 Negative Negative  Luminal A breast cancer Yes 
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4. CONCLUSION 
Although there are recurrent mutations, which appear repeatedly in unrelated families, with peak 
prevalence, as in the Jewish ethnic, this is the first study on the population of the province of Córdoba, 
Argentina. Finally, we have found polymorphisms, sequence variations that involves a nucleotide 
substitution and the resulting amino acid change, but with no clinical relevance relating to BC, due to 
their very low frequency ≤ 1% in the general population. 
According to Table 3 results, we observe that patients with BC / OC with and without a family history 
have the highest percentage of negative BRCA. Same for patients without BC / OC with a family 
history have a high percentage of negative BRCA. Patients with and without BC / OC with family 
history and positive BRCA show a low percentage of this gene mutated. Regarding the phenotypic 
changes the most predominant in this study was the triple negative subtype. Of the two patients with 
positive BRCA1, do not have tumor and the other patient has Triple negative breast cancer. 
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